Substance / Medication

Cenegermin

Overview

Active Ingredient
cenegermin
RxNorm CUI
2104332

Indications

® OXERVATE(cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.

Labeler: Dompé farmaceutici S.p.A.Updated: 2025-02-05T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Topical Cenegermin for Pediatric Neurotrophic Keratopathy: A Review of the Literature and Systematic Review.
Bakr Mohammad, Eleiwa Taher K, Saeed Hajirah N et al. · Cornea · 2025
PMID: 40815061Meta-Analysis
Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy.
Pedrotti Emilio, Bonacci Erika, Chierego Chiara et al. · Orphanet J Rare Dis · 2022
PMID: 35189948ObservationalFull text (PMC)
Use of Cenegermin in the Presence of Bandage Contact Lenses.
Cheung Albert Y, Shah Amar P, Pierson Kasey L et al. · Cornea · 2022
PMID: 34870623Observational
Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder Stephen C, Massaro-Giordano Mina, Perez Victor L et al. · Ophthalmology · 2020
PMID: 31585826Observational
Topical Cenegermin-Bkbj Dramatically Resolves Neurotrophic Keratitis Associated With Pars Plana Vitrectomy.
Cheng Anny M S, Yassin Shaden H, Gupta Shailesh K et al. · Ophthalmic Surg Lasers Imaging Retina · 2025
PMID: 40085096Case Report
Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy.
Riva Ivano, Micheletti Eleonora, Fausto Riccardo et al. · Eur J Ophthalmol · 2022
PMID: 33657894Case Report
Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation.
White Craig A, Affeldt John · Am J Ophthalmol Case Rep · 2022
PMID: 35647393Case ReportFull text (PMC)
Neurotrophic keratopathy: Clinical presentation and effects of cenegermin.
Bu Julia Bing, Gericke Adrian, Pfeiffer Norbert et al. · Am J Ophthalmol Case Rep · 2022
PMID: 35330588Case ReportFull text (PMC)
Acute Calcific Band Keratopathy as an Adverse Effect of Recombinant Human Nerve Growth Factor (Cenegermin): A Multicenter Case Series.
Qureshi Sana, Ferguson Tanner J, Lim Mira et al. · Cornea · 2022
PMID: 34582138Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cenegermin (substance)
SNOMED CT
773954004
UMLS CUI
C4541383
RxNorm CUI
2104332
Labeler
Dompé farmaceutici S.p.A.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.